Literature DB >> 1582604

Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.

E A Masson1, J M Rhodes.   

Abstract

Nephrotoxicity in association with 5-aminosalicylic acid therapy is well recognised. In this patient the nephrotoxicity only became apparent after severe weight loss had occurred in association with nephrogenic diabetes insipidus. The patient aged 26 with ulcerative colitis received resin coated mesalazine (Asacol) 1200 mg/day and lost 12 kg in weight over a four month period, only complaining of thirst towards the end of this period.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582604      PMCID: PMC1374079          DOI: 10.1136/gut.33.4.563

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Acute interstitial nephritis due to 5-aminosalicylic acid.

Authors:  R P Mehta
Journal:  CMAJ       Date:  1990-11-15       Impact factor: 8.262

Review 2.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

3.  Nephrotic syndrome associated with sulphasalazine.

Authors:  V M Barbour; P F Williams
Journal:  BMJ       Date:  1990-10-06

Review 4.  Allergic interstitial nephritis: clinical features and pathogenesis.

Authors:  J S Cameron
Journal:  Q J Med       Date:  1988-02

5.  Nephrotic syndrome after treatment with 5-aminosalicylic acid.

Authors:  B H Novis; Z Korzets; P Chen; J Bernheim
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

6.  Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

Authors:  M J Dew; R E Ryder; N Evans; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

7.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

8.  Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

Authors:  L A Christensen; J Fallingborg; K Abildgaard; B A Jacobsen; G Sanchez; S H Hansen; S Bondesen; E F Hvidberg; S N Rasmussen
Journal:  Aliment Pharmacol Ther       Date:  1990-10       Impact factor: 8.171

9.  Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.

Authors:  M J Dew; P Ebden; N S Kidwai; G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

  9 in total
  7 in total

1.  Polyuria and weight-loss associated with cimetidine.

Authors:  P J Mullen
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.

Authors:  Pedro Magalhães-Costa; Leopoldo Matos; Cristina Chagas
Journal:  BMJ Case Rep       Date:  2015-05-02

3.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

4.  Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment.

Authors:  N Siddique; C Farmer; A F Muller
Journal:  Frontline Gastroenterol       Date:  2014-06-04

Review 5.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

6.  Acute kidney injury in a girl with ulcerative colitis and cytomegalovirus-induced focal segmental glomerular sclerosis.

Authors:  Sankar R Chirumamilla; Chun He; Lorraine C Racusen; Ann O Scheimann; Carmen Cuffari
Journal:  World J Pediatr       Date:  2011-08-27       Impact factor: 2.764

Review 7.  Therapeutic potential of growth factors and their antagonists.

Authors:  A Garner
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.